AUA
  • Program
  • Register
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
Topics
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
Resources
  • Program
  • Register
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
May 13, 2026

Double take: Clinical trial looks at doublet treatment for mHSPC

ARASEC evaluates darolutamide plus ADT without chemotherapy.


Professional headshot of a smiling woman with long brown hair wearing a dark blazer and white top
Rana McKay, MD

Level 1 evidence now supports intensified treatment for metastatic hormone-sensitive prostate cancer (mHSPC), including androgen receptor pathway inhibitors combined with androgen deprivation therapy (ADT) and, in some patients, triplet therapy that adds docetaxel. However, a significant number of patients in the United States still receive ADT alone. 
Closing this gap between guideline-concordant care and everyday practice remains one of the most pressing needs in the field.

Rana McKay, MD, professor of medicine, urology and radiation medicine at the University of California, San Diego, and associate director of clinical sciences at the Moores Cancer Center, will be presenting the initial ARASEC data at today’s session P2s: Practice-Changing, Paradigm-Shifting Clinical Trials in Urology: Darolutamide Plus Androgen Deprivation Therapy (ADT) in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): ARASEC—U.S. Prospective, Open-Label Phase 2 Study With an External Control.

Darolutamide is a second-generation androgen receptor pathway inhibitor with a unique structural profile that results in low blood-brain barrier penetration and minimal off-target binding. Consequently, it has demonstrated a favorable tolerability profile in previous phase 3 trials, with incidence rates of fatigue, falls, fractures, cognitive effects and rash comparable to those of placebo 
plus ADT. 

Darolutamide also has fewer clinically significant drug-drug interactions compared with other agents in the class, which is particularly relevant for the mHSPC population, where polypharmacy and comorbidity are common.

“Darolutamide plus ADT is already established as a standard of care in mHSPC, based on the ARASENS triplet regimen with docetaxel. The question ARASEC addresses is whether the doublet of darolutamide plus ADT, without chemotherapy, offers a compelling option for patients in whom docetaxel is not appropriate or not desired. That is a very common clinical scenario,” Dr. McKay said.

The ARASEC data are practice-changing because they provide prospective evidence of darolutamide plus ADT activity in a contemporary U.S. mHSPC population, offering clinicians and patients another option in a setting where treatment intensification remains underutilized. The trial design itself is paradigm-shifting. ARASEC is a prospective, open-label phase 2 study with an external control arm, a methodology that is increasingly relevant as randomization against ADT alone is no longer ethically or practically feasible in this disease. How clinicians generate and interpret evidence from external control designs represents a shift for the field.

“I want to preserve the findings for attendees. What I can say is that the results speak to both the activity of the doublet in a contemporary U.S. population and to the feasibility of the external control methodology. Attendees should come prepared for a discussion not only of the efficacy and safety signals, but of how this kind of evidence fits into our decision making for individual patients.” 
Dr. McKay said.

Interesting Stories
AUA means business: AUA Annual Business Meeting is May 18
Sponsored by AUA
AUA means business: AUA Annual Business Meeting is May 18
Unique formulation of YONSA® (abiraterone acetate) makes it different
Sponsored by Sun Pharma
Unique formulation of YONSA® (abiraterone acetate) makes it different
Book your AUA2026 housing now
Sponsored by AUA
Book your AUA2026 housing now
Find your next big break at AUA2026
Sponsored by AUA
Find your next big break at AUA2026
More Content
Key Takeaways section header with teal background and decorative botanical line illustrations
Meeting Coverage
A field on the move
Jun 16, 2026
Clinical trials infographic showing healthcare icons including research, vaccines, diagnosis, tests, and medical monitoring
Meeting Coverage
P2s at AUA2026: Trials with the power to change practice
Jun 16, 2026
Professional man speaking at ATTA conference podium against black background
Meeting Coverage
Keynote challenges assumptions about cancer screening
Jun 16, 2026
Yellow arrow navigating through blue 3D maze pathway, symbolizing direction and problem-solving
Meeting Coverage
Evolving evidence, evolving guidelines
Jun 16, 2026
Seven team members in orange UA Bruadcats shirts holding a gold trophy at a competition event
Meeting Coverage
FloBros claim Residents Bowl crown
Jun 16, 2026
Five professionals participate in a panel discussion at a conference, seated at a table decorated with green foliage and pink flowers.
Meeting Coverage
Classic controversy
Jun 16, 2026
Five professionals in business attire pose together at a conference, one holding a certificate and award against a blue backdrop.
Meeting Coverage
Residency programs go for the gold
Jun 16, 2026
Red modern light rail train on tracks in downtown urban area with palm trees and high-rise buildings
Meeting Coverage
Save the date for AUA2027
Jun 16, 2026
Promotional graphic showcasing newspaper and publication layouts with featured articles and news sections
Meeting Coverage
Miss something?
Jun 16, 2026
Dr. Rachel S. Rubin, Assistant Clinical Professor of Urology at Georgetown University Hospital, speaking during an AUA 2026 interview
Meeting Coverage
AUA TV: The meeting in motion
Jun 16, 2026
Abstract blue gradient background with overlapping numbers in varying sizes and opacity
Meeting Coverage
AUA2026: By the numbers
May 29, 2026
2026 AUA Award Winners announcement slide with teal background and dark red accent bar
Meeting Coverage
Celebrating excellence in urology
May 29, 2026
AUA
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
© 2026 Ascend Media. All rights reserved.